Mountain Valley MD says it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials
The company said the cancer patent has been filed for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens Mountain Valley MD said it believes the research will have near-immediate application to direct human trials based on safety and efficacy of ivermectin
Mountain Valley MD Holdings Inc. (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ -
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Summary
MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
The Company is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma.
Share this article
Share this article
VANCOUVER, BC, May 4, 2021 /PRNewswire/ - Mountain Valley MD (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) announced it has filed a novel cancer adjuvant patent related to breast cancer, metastatic melanoma, and lung carcinoma.
Mountain Valley MD is a biotech and life sciences company implementing patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology.
MVMD s core technology applied to the Ivermectin drug is unique in that it only uses excipients (substances formulated alongside the active ingredient) that are
currently approved by the FDA.
Concurrent with its novel cancer adjuvant patent, MVMD is beginning pre-clinical trials with third-party cancer Contract Research Organizations (CROs).
Mountain Valley MD proceeds with pre-clinical cancer trials and files a related cancer patent
The company said ivectosol is being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion The firm said its “solubility technology” applied to the ivermectin drug uses “excipients that are approved by the FDA making it a leading candidate for human injection or intravenous infusion
Mountain Valley MD Holdings Inc (CSE:MVMD) (FRA:20MP) (OTCQB:MVMDF) announced that the company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Mountain Valley MD Commencing Trials in Bangladesh, Striking Pharmaceutical Production Agreements
News provided by
Share this article
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials under the supervision of The People s Republic of Bangladesh s Ministry of Fisheries & Livestock for the Company s injectable solubilized Ivermectin technology, Ivectosol™ 1%. We are very excited to be welcoming Mountain Valley MD to The People s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product, stated Bangladesh s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.